Brokerages expect Celsion Co. (NASDAQ:CLSN) to announce sales of $130,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Celsion’s earnings. Celsion also reported sales of $130,000.00 in the same quarter last year. The firm is expected to report its next earnings report on Thursday, March 15th.
On average, analysts expect that Celsion will report full-year sales of $130,000.00 for the current financial year. For the next financial year, analysts forecast that the firm will post sales of $500,000.00 per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Celsion.
CLSN has been the subject of several recent research reports. Maxim Group raised Celsion from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Wednesday, October 4th. Zacks Investment Research upgraded Celsion from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Tuesday, August 29th. Oppenheimer assumed coverage on Celsion in a report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 price objective on the stock. Finally, ValuEngine raised Celsion from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Celsion has a consensus rating of “Buy” and an average target price of $11.90.
Celsion (NASDAQ:CLSN) remained flat at $$2.57 during midday trading on Wednesday. 183,600 shares of the company were exchanged, compared to its average volume of 1,563,648. Celsion has a 52-week low of $1.24 and a 52-week high of $8.82. The stock has a market capitalization of $41.28, a PE ratio of -0.44 and a beta of 1.21.
A hedge fund recently bought a new stake in Celsion stock. Sabby Management LLC purchased a new stake in Celsion Co. (NASDAQ:CLSN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned approximately 1.30% of Celsion as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 3.97% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.truebluetribune.com/2018/01/19/zacks-brokerages-anticipate-celsion-co-clsn-will-post-quarterly-sales-of-130000-00.html.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.